https://www.fiercepharma.com/pharma/incyte-and-novartis-agree-settle-long-running-jakafi-royalty-dispute-just-trial
Interestingly within days of each other Incyte picked up the full commercial rights to anti-CD19 antibody Monjuvi from MorphoSys, its original partner on the drug. Novartis, meanwhile, shelled out $2.9 billion on buying MorphoSys’ other clinical assets.
hmmm... I wonder who was in the bidding war.
https://www.ft.com/content/a46eff5f-7cf5-4a34-8e82-bc13ce3223cc
Novartis are shelling out $23 billion over the next 5 years to set up US manufacturing plants.
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-regulus-therapeutics-up-17-billion-2025-04-30/
They are still buying assets. They paid $800 mill for an upfront deal a few days ago and another possible $800 million if the drug gets approval.
https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/cash-on-hand?utm_source=chatgpt.com
Burning cash but still have $7.1 billion of cash at the end of the first quarter.
I wonder how much buying MorphoSy's has burnt them and if they are still looking to add to their MF portfolio.
Add to My Watchlist
What is My Watchlist?
